Short-term renal and patient outcomes of primary immunoglobulin-associated mesangiocapillary glomerulonephritis: Insights from a developing country

Table 4 Comparison between renal outcomes and baseline clinicopathological parameters in patients with primary immunoglobulin-associated mesangiocapillary glomerulonephritis

Variables	Complete remission, n = 56	Partial remission, n = 68	End-stage kidney disease, n = 32	Mortality, n = 7	P value
Age in years	32.71 ± 9.84	35.71 ± 13.4	28.44 ± 11.41	29.86 ± 13.50	0.03
Hypertension	24 (42.85)	21 (30.8)	10 (31.25)	2 (28.57)	0.50
Serum creatinine in mg/dL	1.94 ± 1.43	2.36 ± 2.52	4.51 ± 4.49	4.69 ± 4.12	< 0.001
Serum albumin in g/dL	2.72 ± 0.76	2.23 ± 0.76	1.78 ± 0.59	1.90 ± 0.50	< 0.001
protein-to-creatinine ratio in g/dL	3.93 ± 0.879	3.73 ± 0.595	4.22 ± 0.553	3.86 ± 3.78	0.114
Estimated glomerular filtration rate in mL/minute/1.73 m2	60.33 ± 31.07	57.87 ± 41.83	38.54 ± 37.14	28.20 ± 18.31	0.01
Required kidney replacement therapy on admission	3 (5.35)	5 (7.35)	29 (90.62)	6 (85.71)	< 0.001
Serum C3 levels
Low, < 0.8 g/L	27 (48.21)	31 (45.5)	17 (53.12)	4 (57.14)	0.84
Normal, > 0.8 g/L	24 (42.85)	30 (44.11)	11 (34.37)	3 (42.85)
Serum C4 levels
Low, < 0.16 g/L	17 (30.35)	13 (19.11)	4 (12.5)	1 (14.28)	0.19
Normal, > 0.16 g/L	33 (58.92)	49 (72)	24 (75)	5 (71.42)
Number of globally sclerosed glomeruli	0.45 ± 0.80	1.75 ± 2.42	5.27 ± 5.64	3.86 ± 5.36	< 0.001
Presence of crescents	10 (17.85)	25 (36.7)	17 (53.12)	5 (71.42)	< 0.001
Mesangial/endocapillary proliferation
Focal	17 (30.35)	15 (22)	4 (12.5)	0	0.128
Diffuse	39 (69.64)	52 (76.47)	28 (87.5)	7 (100)
Presence of spikes	0	12 (17.6)	3 (9.37)	0	0.006
Interstitial fibrosis and tubular atrophy
None	16 (28.57)	5 (7.35)	2 (6.25)	0
Mild	37 (66.07)	49 (72)	14 (43.75)	1 (14.28)	< 0.001
Moderate	3 (5.35)	13 (19.11)	13 (40.62)	6 (85.71)
Severe	0	0	3 (9.37)	0

Data are n (%) or mean ± standard deviation.